Key findings

  • 15% vs 28%of patients with stage II colon cancer received adjuvant chemotherapy when managed by ctDNA result versus conventionally in the DYNAMIC trial, with 2-year recurrence-free survival non-inferior (93.5% vs 92.4%)
  • 16.8%of stage I cancers were detected by a targeted methylation multi-cancer early detection test in the CCGA validation cohort, against 51.5% of all cancers
  • 38%positive predictive value in PATHFINDER: of 6621 people offered the test, ninety-two (1.4%) had a positive result and cancer was confirmed in 35
  • 81.6% and 53.2%of plasma mutations bore the hallmarks of clonal haematopoiesis in people without cancer and with metastatic cancer, respectively

Abstract

Background
Cancer incidence is rising worldwide and in India. Diagnosis still relies on tissue biopsy, which is invasive, hard to repeat, and samples only part of a heterogeneous tumour. Circulating tumour DNA, the small tumour-derived share of plasma cell-free DNA, can be sampled repeatedly at little risk and is the most clinically advanced liquid-biopsy analyte.
Objective
To appraise circulating tumour DNA testing in adult solid tumours from the perspective of the clinical biochemistry laboratory, covering the biological and pre-analytical determinants of performance, the analytical platforms, the evidence for three clinical uses, and implementation in low- and middle-income countries.
Methods
Literature published from January 2008 to December 2025 was retrieved from Scopus, PubMed, Google Scholar, and Web of Science. Only peer-reviewed articles in English were considered, and guidelines, randomised trials, and prospective studies were weighted most heavily.
Results
Plasma genotyping in advanced cancer is supported by guidelines, provided that negative results are followed by tissue testing. After curative surgery, a positive test identifies patients likely to relapse; in one randomised trial in stage II colon cancer, basing adjuvant therapy on the result lowered chemotherapy use while recurrence-free survival stayed noninferior. Multi-cancer early detection is highly specific but insensitive for stage I disease, and its mortality benefit is unproven. Clonal haematopoiesis, low tumour shedding, and non-standardised sample handling cause most false results.
Conclusion
Circulating tumour DNA testing is ready for routine use in selected indications. Wider adoption depends on standardised sample handling, filtering of clonal haematopoiesis variants, external quality assessment, and stepwise implementation.

Highlights / Key Points

  • Circulating tumour DNA is the most clinically mature liquid-biopsy analyte and the focus of this review.
  • Pre-analytical handling and clonal haematopoiesis are major, controllable sources of false results.
  • Plasma genotyping in advanced cancer is guideline-supported, but a negative result still needs tissue testing.
  • Residual-disease testing after surgery is prognostic, and early randomised data support test-guided de-escalation.
  • Multi-cancer early detection is specific but insensitive for stage I disease; mortality benefit is unproven.

Introduction

Global and Indian cancer burden

Cancer and other non-communicable diseases now threaten global development, and progress under the 2011 United Nations Political Declaration on these diseases and the third Sustainable Development Goal has been slow.1 The Goals aim to reduce premature deaths from non-communicable disease by a third before 2030; even so, projections show the cancer burden growing for at least another 20 years.2 India is no exception. Cancer is a major cause of illness and death there, and case numbers rise every year despite better treatment.3 Registry-based incidence estimates for 2022, broken down by sex, age, and site, now give planners the data they need to design and evaluate control programmes.4 Against this background, any test that can find cancer earlier, guide treatment more precisely, or follow disease without repeated invasive procedures has clear public-health value.

Shortcomings of tissue sampling

Histological examination of tissue is still the standard against which other diagnostic methods are judged. Its laboratory procedures are well standardised, specimens are stable, and analytical accuracy is high; it is also the usual basis for tumour classification and biomarker testing.5 Its limitations are equally well known. The procedure is invasive, cannot always be repeated, and captures the tumour at a single site and time point, so spatial and temporal heterogeneity are incompletely represented.6 Repeated invasive sampling to follow tumour genotype during treatment is rarely feasible,7 and a single specimen from a heterogeneous tumour is likely to underestimate its mutational diversity.5 These limitations matter most in advanced disease, when treatment decisions depend on the current molecular state of the tumour rather than on its state at diagnosis.

Liquid biopsy and the rise of circulating tumour DNA

The term liquid biopsy covers any test that examines material released by a tumour into blood or another body fluid. Interest in the approach has grown because it allows repeated, minimally invasive sampling that can follow the changing behaviour of a cancer over time.8 It is now used as a complement to tissue sampling across the phases of cancer management9 and has changed how oncologists approach treatment selection and monitoring.10 Among the available analytes, circulating tumour DNA (ctDNA) has progressed furthest towards routine care: most regulator-cleared liquid-biopsy assays are based on it, and it is the analyte most often evaluated in prospective clinical studies.7,10

Role of clinical biochemistry laboratories in molecular oncology

Tissue biopsy is used, when the tumour is accessible, for diagnosis, staging, and assessment of treatment response.11 Tumour-derived components shed into the circulation can add longitudinal information that supports the diagnosis of both primary and metastatic disease.6 Laboratories offering liquid-biopsy tests may nevertheless need an initial histological diagnosis from tissue to avoid over-interpretation of plasma findings.6 Protein signatures carried by circulating extracellular vesicles and particles have also been proposed for future monitoring.11 Many of the steps that decide whether a ctDNA result is reliable, including blood collection, tube type, time to centrifugation, extraction, quantification, quality control, and reporting, are core competencies of clinical biochemistry laboratories. The laboratory is therefore not only where these tests are performed but also where most avoidable errors can be prevented.

Rationale, aim, and scope of the review

Recent reviews describe liquid biopsy broadly, covering several analytes, platforms, and applications in parallel.5,6 This breadth is useful for orientation, but it leaves little room to judge the strength of the evidence for any single use or to address the practical questions a laboratory faces when it introduces a test. We therefore limited this review to one analyte and one viewpoint. Its aim is to critically appraise ctDNA testing in adult solid tumours from the perspective of the clinical biochemistry laboratory. The objectives are (i) to explain the biological and pre-analytical factors that limit sensitivity and specificity; (ii) to compare the main analytical platforms and their fitness for different clinical questions; (iii) to evaluate the evidence for three uses, namely treatment selection in advanced disease, detection of molecular residual disease after curative treatment, and multi-cancer early detection; and (iv) to outline what implementation requires in resource-limited settings such as India. Other circulating analytes (tumour cells, RNA, vesicles, and platelets) receive only a short summary that puts ctDNA in context. Haematological malignancies, non-oncological uses of cell-free DNA, and therapeutic applications are outside the scope. Figure 1 summarises the workflow considered in this review.

Figure 1. Circulating tumour DNA testing pathway considered in this review, from tumour shedding to clinical use. Column 4 shows the current level of evidence for each use. Other analytes are shown in grey for context only. Abbreviations are defined in the Abbreviations list.

Methods

The review is narrative in design, although the literature was identified through a predefined search. A narrative format was chosen because the questions addressed, which are biological, analytical, clinical, and organisational, are too heterogeneous for quantitative pooling. The review protocol was not registered.

Search strategy. We searched Scopus, PubMed, Google Scholar, and Web of Science for material published from January 1, 2008, to December 31, 2025. The PubMed query combined Medical Subject Headings with free-text terms: ("Liquid Biopsy"[MeSH] OR "liquid biopsy" OR "Circulating Tumor DNA"[MeSH] OR "circulating tumour DNA" OR ctDNA OR "cell-free DNA" OR cfDNA) AND (Neoplasms[MeSH] OR cancer OR tumour OR tumor) AND (pre-analytical OR "digital PCR" OR "next-generation sequencing" OR "minimal residual disease" OR "molecular residual disease" OR "multi-cancer early detection" OR "companion diagnostic" OR "quality control" OR regulation OR cost). Equivalent strings were written for the other databases. For the brief section on other analytes, additional searches covered exosomes and extracellular vesicles, tumour-educated platelets, microRNA and cell-free RNA, and circulating tumour cells. Reference lists of key reviews and guidelines were also checked.

Eligibility criteria. We included peer-reviewed articles in English that dealt with ctDNA or cell-free DNA in human solid tumours. Eligible designs were primary research, systematic or narrative reviews, meta-analyses, and guidance or consensus statements issued by professional or regulatory bodies. We excluded conference abstracts, editorials without data, preprints, non-English articles, and studies limited to non-cancer applications.

Study selection, data extraction, and synthesis. One author carried out the initial screen on title and abstract and then read in full every record that might qualify; where eligibility was unclear, the decision was made jointly with the corresponding author. When several studies addressed the same question, most weight was given to clinical practice guidelines and consensus statements, followed by randomised trials, then prospective cohorts, then pooled analyses, and lastly retrospective and analytical work. For each included study, the analyte, platform, tumour type, clinical setting, sample size, and main performance or outcome measures were recorded. Findings were synthesised thematically under the four objectives, and the strength and limitations of the evidence for each clinical use are appraised in the Discussion. No formal risk-of-bias assessment was performed, which is acknowledged as a limitation.

Biological Basis of Circulating Tumour DNA

Definition and origin

Liquid biopsy rests on the idea that a blood sample, taken at any point in the course of the disease, can report on the tumour, although how fully this will be realised in routine care is still under study.12 In blood, the analysis may target intact tumour cells, cell-free nucleic acids, or vesicles released by the primary tumour and its metastases.12 Most of the cell-free DNA (cfDNA) in plasma is released as cells die, and in healthy people the bulk derives from blood-forming cells; ctDNA is the portion that tumour cells contribute.7,13

Fragment size, abundance, and kinetics

Because ctDNA is released largely through apoptosis and necrosis, most fragments are short, and tumour-derived fragments are on average slightly shorter than those released by healthy cells. Enriching for short fragments during library preparation or analysis can therefore strengthen the tumour signal.14 The tumour fraction varies widely. In advanced disease it can be above 10% of all cfDNA, but it is much lower when tumours are small and in certain cancers, gliomas and renal tumours among them.14 ctDNA is cleared rapidly, with a half-life of less than 2 hours, so its concentration reflects current tumour burden and falls within days of surgery or effective treatment.15 These properties, namely short fragments, low and variable abundance, and rapid turnover, explain both the appeal of ctDNA as a real-time marker and its main weakness, which is limited sensitivity when the tumour burden is low.7

Other circulating analytes in context

Tumour cells can also detach from a primary or secondary lesion and circulate intact. These circulating tumour cells (CTCs) preserve morphology, surface proteins, DNA, and RNA, but they are so scarce that some form of enrichment is always needed.6,13 Circulating RNA, microRNAs included, is being evaluated as a monitoring marker in oncology and in several benign conditions; the first cancer studies of this analyte dealt mostly with non-coding species.16

Every cell sheds extracellular vesicles, membrane-enclosed particles that are conventionally grouped by size and mode of formation into microvesicles, exosomes, and apoptotic bodies.17 Exosomes are the smallest, about 30–150 nm across. They form within endosomes, and their cargo of proteins, lipids, DNA, and RNA mirrors the cell that released them, which allows them to carry signals between cells in normal and diseased tissue alike.11,18–20 Cancer cells release them in large numbers, and protein profiles of vesicles and related particles can separate several tumour types.11,18 No isolation method has yet become standard, however.19

Platelets exposed to a tumour take up its RNA, proteins, and vesicles, and their own RNA and protein profiles change as a result, although clotting function seems largely preserved.21–23 These altered platelet signatures are being tested for cancer detection and for locating the primary site, but none is yet in routine diagnostic use.22,24

Table 1 compares these analytes with ctDNA. Each provides information that ctDNA cannot, such as whole-cell biology from CTCs, transcriptional activity from RNA, and protein cargo from vesicles and platelets. Apart from CTC enumeration for prognosis, which United States regulators have allowed since 2004,25 none of these analytes yet has clinical-utility data on the scale available for ctDNA. This difference in maturity is the reason for the focus of the present review.

Table 1. Circulating analytes used in liquid biopsy: source, properties, main use, and main limitation.

AnalytePrimary sourceKey propertiesRepresentative clinical useMain limitation
CTCsPrimary / metastatic tumour sheddingIntact tumour cells; rare (<1 per 106 leukocytes); capture whole-cell biologyPrognosis; longitudinal monitoring in lung, breast, prostate, colorectal cancerVery low abundance; enrichment bias
ctDNATumour cell apoptosis / necrosisShort fragments (~160 bp); half-life <2 h; real-time dynamicsMRD detection; resistance tracking; companion diagnostics (EGFR, KRAS, NTRK)CHIP; dilution in low-burden disease
cfRNA / miRNAActive and passive releaseIncludes mRNA and noncoding RNA; profile reflects transcriptional stateEarly detection signatures; tissue-of-origin inferencePre-analytical fragility; standardisation gaps
EVs / exosomesAll cell types (endosomal origin)30–150 nm lipid nanovesicles; carry DNA, RNA, protein, lipidsOrgan-specific biomarker profiling; therapeutic vectorsIsolation heterogeneity; subpopulation overlap
TEPsPlatelet uptake / splicingModified RNA and protein repertoires after tumour contactMulti-cancer screening signatures; organ-of-origin cluesAwaiting routine clinical validation

CTC, circulating tumour cell; ctDNA, circulating tumour DNA; cfRNA, cell-free RNA; miRNA, microRNA; mRNA, messenger RNA; EV, extracellular vesicle; TEP, tumour-educated platelet; MRD, molecular residual disease; CHIP, clonal haematopoiesis of indeterminate potential.

Sample matrices

Blood is the principal matrix for ctDNA analysis, but tumour DNA can also be recovered from urine, saliva, cerebrospinal fluid, pleural effusion, and ascites.13,18,26 These fluids are mainly of interest for tumours in direct contact with them, such as urothelial cancers and urine or brain tumours and cerebrospinal fluid.13 Long cfDNA fragments have been sequenced from plasma and urine using nanopore technology, allowing real-time analysis of tumour genomes and fragment patterns.27 Saliva can be collected without any procedure, but it needs its own pre-analytical protocols.28 For the indications considered here, plasma remains the matrix with the strongest supporting evidence.

Pre-analytical determinants of test performance

The clinical sensitivity of a cfDNA test is limited as much by what happens before analysis as by the assay itself.29 Collection tube, time and temperature before centrifugation, centrifugation protocol, storage, and extraction method all change the quantity, quality, and fragment profile of the recovered DNA.29,30 The most important problem is contamination of plasma by genomic DNA from white cells that lyse after blood is drawn. This DNA dilutes the tumour fraction, which is often very low in early-stage disease, and can push a true variant below the limit of detection.14,30 Stabilising tubes limit this lysis and allow longer transport, whereas standard ethylenediaminetetraacetic acid (EDTA) tubes need rapid processing.30 Plasma should be separated by a two-step centrifugation that removes residual cells and platelets.31 Each specimen type needs its own pipeline, and saliva in particular requires further work.28 Pre-analytical procedures are still not harmonised across studies, which is one reason why published results conflict.30 Even a perfectly handled sample contains only a small amount of tumour-derived material, and variants arising from clonal haematopoiesis of indeterminate potential (CHIP) can be mistaken for tumour mutations, particularly in older patients.13 These issues are discussed further in Section 8.4.

Analytical Platforms for Circulating Tumour DNA

Digital PCR

Digital polymerase chain reaction (PCR) works by dividing the reaction mixture into a very large number of small partitions. Each partition holds either no copy of the target or only a few, so after amplification the proportion of positive partitions can be converted directly into a copy number. No calibration curve is needed, and small differences in amplification efficiency hardly affect the result.32 Droplet digital PCR (ddPCR) creates the partitions as thousands of nanolitre-sized droplets.32,33 For ctDNA work it is inexpensive per test and fast, and it can find a known variant even when that variant makes up only a small fraction of the DNA. The trade-off is scope: each assay looks for one or a few predefined changes. ddPCR therefore suits questions in which the target is already known, such as checking for a single resistance mutation or tracking a mutation first found in the tumour. Many laboratories also use it to quantify DNA and sequencing libraries during larger workflows.32

Next-generation sequencing

In next-generation sequencing (NGS), very large numbers of DNA fragments are read in a single run, so many genomic regions can be covered at once.16,34 Cell-free DNA sequencing first reached the clinic in prenatal testing for trisomy 21,16 and as costs fell and accuracy improved, NGS became the main tool for ctDNA profiling in cancer.26,35 Which approach to use depends on how much tumour DNA the sample is likely to contain. A small panel sequenced to great depth can pick up low ctDNA levels, whereas exome-wide or low-coverage genome-wide sequencing usually needs a tumour fraction of around 10% or more to be informative.14 At very low allele fractions, errors introduced during amplification and sequencing set the detection limit. Tagging each starting molecule with a unique barcode and computationally removing recurrent background errors, an approach known as integrated digital error suppression, lowers the error rate without sacrificing recovered genome equivalents.36 Two further choices matter in the clinic. Tumour-agnostic panels need no tissue and underlie most plasma genotyping tests. Tumour-informed assays begin by sequencing the patient's own tumour and then search plasma for a personalised set of its variants, which gives higher sensitivity for residual disease.37 Fragment-length patterns and methylation profiles in cfDNA can also show whether cancer is present and where it probably arose.38,39

CRISPR-based and other emerging detection methods

In CRISPR-based detection, the target is first amplified at a constant temperature; a Cas enzyme then recognises it and, once activated, cuts a labelled reporter to generate a signal. SHERLOCK, which uses Cas13a, has reached attomolar sensitivity for DNA and RNA and can tell apart sequences that differ at a single base.40,41 Speed and minimal equipment make such assays attractive for point-of-care use; a Cas13a system has, for example, been used to detect vesicle-borne microRNAs linked to colorectal cancer.24 CRISPR tools combined with NGS may also help identify drug targets more quickly.42 For ctDNA itself, clinical validation is still thin, and CRISPR assays cannot yet replace ddPCR or NGS in routine work.

Protein-based and nanotechnology approaches

Several hundred proteins can be measured together in liquid-biopsy samples by mass spectrometry, antibody or antigen arrays, aptamer platforms, proximity-extension assays, or reverse-phase protein arrays.24 Bead-based multiplex immunoassays are common; in prostate cancer that no longer responds to castration, for example, enzyme immunoassays measured plasma cytokeratin 18 both intact and after caspase cleavage.24,43 Mass spectrometry has shown which proteins are enriched in large rather than small extracellular vesicles.44 Applied to blood, it has identified extramedullary spread of multiple myeloma, and a machine-learning model built on mass-spectrometry data has been proposed as a way to find pancreatic cancer at an earlier stage.45,46 Nanomaterials allow biosensors to be miniaturised,47 and the nucleic acid-linked immuno-sandwich assay (NULISA) lowers the detection limit of immunoassays to attomolar concentrations while measuring many proteins in one reaction.48 Proteins may point to the organ of origin better than DNA does,24 and portable formats could one day take such tests outside central laboratories.26,47 For now, though, these are mostly research methods that add to ctDNA analysis rather than replace it.

Quality control, reproducibility, and standardisation

Reliable ctDNA testing depends on quality control at every step. Harmonisation of methods, interpretation, and integration into clinical practice is still incomplete, and shared approaches make it easier to compare data across centres.26 There is growing agreement on preferred collection and processing procedures, and the lack of a consistent extraction protocol has been identified as a barrier to clinical adoption.49 Reproducible and accurate results require validated, optimised procedures and standardisation of the whole analytical pathway.50 In practice, laboratories need three layers of control: internal quality control with each run, including a no-template control and a positive control close to the limit of detection; participation in external quality assessment or proficiency testing; and information systems that track both.49,51 Reference materials with certified low variant allele fractions are particularly valuable, because assay performance is most likely to fail near the detection limit.

Clinical Applications of Circulating Tumour DNA

Early detection and screening

Cancer control depends heavily on finding disease early: tumours caught at an early stage can often be removed and cured, whereas most recurrent or metastatic cancers cannot be cured with the treatments now available.52 Screening seeks to detect cancer before it causes symptoms and sometimes to find premalignant lesions.53 Only a few cancers have established screening programmes, and some of these are offered only to people at high risk.54 Late diagnosis remains common, and roughly one in three patients diagnosed with early-stage cancer will later face a risk of recurrence.37

Most liquid-biopsy testing today concerns advanced disease, and screening requires higher sensitivity at low tumour burden.6 Tests for multi-cancer early detection (MCED), which mostly rely on cfDNA, look for a signal common to many cancer types and then estimate the organ in which it arose.53 In England, the NHS-Galleri randomised trial has enrolled about 140000 people without symptoms to find out whether adding such a test to usual care lowers the number of cancers diagnosed at a late stage.55 Its use of stage at diagnosis as the primary end point has been debated, because stage shift is only a surrogate for mortality.56 Translational reviews stress that MCED tests must show benefit on clinically meaningful end points and that harms from false-positive results and overdiagnosis must be measured.57 The available performance data are appraised in Section 8.3.

Companion diagnostics and molecular stratification

Knowing which genomic alterations drive an advanced cancer makes biomarker-guided targeted treatment possible for an expanding range of tumours.13 These drugs have become a mainstay of oncology, but they help only when the relevant alteration has been correctly identified.58 With standardised protocols, tight quality control, and high-throughput sequencing, plasma can be tested for a single gene or with a broad panel.58 Plasma results come faster than tissue results and can still be obtained when the biopsy sample is too small or a new biopsy would be unsafe. The first ctDNA assay approved as a companion diagnostic was a plasma test for mutations in the epidermal growth factor receptor (EGFR) gene in advanced non-small-cell lung cancer (NSCLC),25 and treatment in this disease can now be chosen from plasma results without a repeat biopsy.59 Broad plasma panels also find uncommon but treatable changes, such as fusions of the neurotrophic tyrosine receptor kinase (NTRK) genes, which respond durably to the tropomyosin receptor kinase inhibitors larotrectinib and entrectinib.60 Fusions and copy-number changes are, however, detected less reliably in plasma than in tissue.61

Molecular residual disease and response monitoring

Molecular residual disease (MRD) is tumour DNA found in plasma after curative-intent treatment, before relapse can be seen on imaging. Patients without detectable ctDNA generally do much better.62 ctDNA levels rise and fall with tumour burden, as first shown in colorectal cancer,15 and early changes during chemotherapy have predicted response in several tumour types, among them liver, pancreatic, lung, and colorectal cancers.38 Change from the baseline level is increasingly used as an early surrogate of response.62 The strongest evidence comes from colorectal cancer. Higher-risk patients receive adjuvant chemotherapy after curative surgery, yet many still relapse, and a meta-analysis found that ctDNA detected after surgery marks out those at high risk of recurrence.63 Tumour-informed assays are usually more sensitive for MRD than tumour-agnostic panels, but they need tumour tissue and take longer to deliver the first result.37 Whether acting on an MRD result improves survival is the central open question and is discussed in Section 8.2.

Resistance monitoring

Liquid biopsy is increasingly used for diagnosis and prognosis in oncology.64 In EGFR-mutant lung cancer, plasma testing guides targeted therapy and allows repeat genotyping at progression without rebiopsy.59 Anaplastic lymphoma kinase (ALK)-positive lung cancer illustrates the value of serial testing, because mutations conferring resistance to ALK inhibitors can be identified in ctDNA and used to choose the next line of treatment.65 Serial plasma testing can also detect emerging resistance before clinical progression, but acting on such molecular progression is not yet standard practice.61 Platelets continuously sample the circulation and take up tumour-derived material, and they may add information on tumour behaviour in the future.66

Paediatric cancers

Survival in paediatric cancer has improved markedly, and the current aim is to maintain it while reducing treatment toxicity, which requires detailed molecular characterisation of each tumour. Liquid biopsy can provide this when tissue is inaccessible or scarce.67 ctDNA and cfRNA have been studied in paediatric solid and brain tumours for prognosis, tumour evolution, and treatment response; in brain tumours, cerebrospinal fluid often yields more tumour DNA than plasma.68,69 Evidence in children still comes mainly from small cohorts.

Comparative summary: liquid biopsy versus tissue biopsy

Table 2 sets out how liquid and tissue biopsy differ in practice. Neither replaces the other. Tissue shows the histology and structure of the tumour, whereas plasma can be sampled repeatedly at little risk and reports on the tumour's current molecular state.

Table 2. Comparison of liquid biopsy and tissue biopsy in oncology practice.

DimensionLiquid biopsyTissue biopsy
Procedural riskLow: blood draw or collection of urine or salivaRequires a procedure; complications possible with deep-seated lesions
RepeatabilityEasily repeatable; supports longitudinal samplingLimited; often unfeasible at multiple time points
Tumour heterogeneityCaptures systemic heterogeneity of all shedding lesionsSamples a single spatial coordinate; may miss subclones
Turnaround timeDays once pipelines are validatedUsually 5–10 days, including fixation, processing, and reporting
Range of analytesNucleic acids, proteins, vesicles, and intact cellsMorphology, immunohistochemistry, and targeted molecular tests
Sensitivity limitationLow analyte fraction in low-burden disease; CHIP confoundingToo few viable tumour cells, or a sample that is not representative
Regulatory positionSome assays cleared by FDA, EMA, or CDSCO; many remain research toolsAccepted reference method in all jurisdictions
Main usesTreatment selection, MRD, resistance monitoring; MCED within studiesPrimary diagnosis, grading, staging, and tumour biology

Implementation in the Clinical Biochemistry Laboratory

Laboratory workflow adaptation

Many laboratories already run PCR-based ctDNA tests, but these methods examine only a few mutations at a time.70 Moving to broader testing affects every step, from receiving and extracting the sample through library preparation and sequencing to bioinformatic analysis, and each step must be timed so that results still arrive before clinical decisions are made.49 Extraction systems that are standardised and partly automated reduce variation between operators and have been validated for cfDNA.70 One workable arrangement is a tiered menu: ddPCR when a single known variant is sought, a validated targeted NGS panel for genotyping, and referral of tumour-informed MRD testing to specialised centres until local demand justifies bringing it in-house.

Sample processing and biobanking

For plasma cfDNA, blood is centrifuged twice to remove residual cells and debris, and the buffy coat can be kept for germline or white-cell sequencing; for CTC work, the same steps remove platelets and red cells before enrichment.31,49 Extraction chemistry also affects yield and fragment profile, so each extraction method should be validated for each specimen type.70 Biobanked plasma should be stored in aliquots to avoid repeated freeze-thaw cycles, with records of tube type, processing times, and storage duration so that pre-analytical variables can be taken into account later.49

Data management and bioinformatics

ctDNA sequencing produces large datasets that need a validated bioinformatics pipeline. The first step maps each read to its position in the human genome, using software such as the Burrows-Wheeler Aligner; programs such as MuTect, VarScan, Strelka, or GATK then call point mutations and short indels.50 Methylation-based methods, including cell-free methylated DNA immunoprecipitation sequencing and bisulphite or enzymatic methyl-sequencing, generate genome-wide profiles that are reduced to classifier features to infer the tissue of origin.39 Pipelines must be version-controlled and revalidated after each change, and sequencing data require secure storage because they can identify the patient and their relatives.

Clinical reporting, validation, and interpretation

Every ctDNA assay a laboratory uses must first be validated, both analytically and clinically.49 Plasma and tissue tests do not always detect the same variants, so a positive or negative plasma result has to be read in light of the assay's limit of detection and the likelihood of an alteration before testing.49 Reports should give the variant allele fraction of each finding and, where possible, an estimate of tumour fraction, and should state whether a negative result is informative; in a patient whose tumour sheds little DNA, a negative plasma test does not rule out an actionable alteration.61 Low-level calls should be confirmed by a second method, clinicians need a clear account of how CHIP variants were handled,49,71 and laboratories should join external quality assessment so that results can be compared between sites and instruments.71

Regulatory, Ethical, and Economic Considerations

Global and Indian regulatory frameworks

Regulation of liquid-biopsy tests differs between regions. In the United States, in vitro diagnostics are regulated by the Food and Drug Administration (FDA) according to their risk class. The agency cleared CellSearch for prognostic CTC counts in 2004 and, in 2016, the cobas plasma test for EGFR mutations,25 followed in 2020 by broad plasma genotyping panels approved as companion diagnostics. Selected examples appear in Table 3. European Union requirements for diagnostics are set out in Regulation (EU) 2017/746 on in vitro diagnostic devices; notified bodies carry out the assessment and consult the European Medicines Agency on companion diagnostics. In India, oversight of drugs and medical devices rests with the Central Drugs Standard Control Organisation (CDSCO), and ethical guidance for biomedical research is issued by the Indian Council of Medical Research (ICMR).72 A large share of ctDNA tests, MCED tests among them, are marketed as laboratory-developed tests and receive less regulatory scrutiny than cleared devices.

Table 3. Regulatory status of selected liquid-biopsy assays.

AssayAnalyteIndicationAuthorityYear
CellSearchCTCs (EpCAM+ / CK+ / CD45−)Prognosis in metastatic breast, prostate, colorectal cancerFDA2004
cobas EGFR Mutation Test v2Plasma cfDNA — EGFR exon 19 / L858R / T790MCompanion diagnostic for EGFR-TKIs in NSCLCFDA2016
FoundationOne Liquid CDxPlasma cfDNA — 300+ genesComprehensive profiling; companion diagnosticFDA2020
Guardant360 CDxPlasma cfDNA — 55–74 genesAdvanced solid tumour profiling; companion diagnosticFDA2020
Epi proColonPlasma SEPT9 methylationColorectal-cancer screeningFDA2016
Galleri (MCED)Plasma cfDNA methylation — >50 cancer signalsMCED in asymptomatic adults (screening-pathway studies)LDT / investigational2021+

EpCAM, epithelial cell adhesion molecule; CK, cytokeratin; TKI, tyrosine kinase inhibitor; NSCLC, non-small-cell lung cancer; LDT, laboratory-developed test; SEPT9, Septin 9.

Ethical issues

Consent, incidental findings, and data governance are the main ethical concerns. Because some assays detect inherited variants alongside tumour-specific ones, clinicians and laboratories should agree beforehand how patients will be counselled and where those with actionable germline results will be referred.73 Very sensitive tests may also detect cancers that would never have caused harm, leading to overdiagnosis, unnecessary treatment, and anxiety.74 Sequence data identify the patient and can reveal information about relatives, so clear rules on storage, access, and secondary use are needed.

Cost-effectiveness and access in LMIC settings

Cost-effectiveness increasingly decides whether a molecular test is adopted, and nowhere more so than in countries with low and middle incomes (LMICs).75 A fair comparison weighs the price of the test against the costs it may avoid, such as additional imaging, a second biopsy, or delayed or wrong treatment; even so, reagents and instruments remain too expensive for many resource-limited settings.75 We suggest that LMIC laboratories begin with a small number of high-value uses, for instance plasma EGFR testing by ddPCR or a small panel when a patient with advanced NSCLC has insufficient tissue, and widen the menu only as workload, skills, and reimbursement allow. A hub-and-spoke model, in which district hospitals collect and stabilise samples for an accredited regional laboratory, may reach more patients than equipping every hospital.

Precision oncology in public-health cancer care

Matching treatment to each tumour's molecular profile has raised expectations of cancer care, in haematological cancers such as multiple myeloma as well as in solid tumours.76 Bringing ctDNA testing into public cancer services will need joint planning of laboratory capacity, staff training, payment, and registries; clinical trials, meanwhile, increasingly select patients on molecular grounds and use liquid-biopsy end points.77

Discussion

This review set out to appraise ctDNA testing from the laboratory's point of view. Three conclusions emerge. First, the evidence differs sharply between uses: plasma genotyping in advanced cancer is supported by guidelines, MRD testing is prognostic and has early randomised support in colon cancer, and MCED remains investigational. Second, many false results arise from avoidable pre-analytical and interpretive errors rather than from the limits of the analytical platforms. Third, the main barriers to wider use are organisational and economic rather than technological. The following sections examine these points and their implications for practice.

Treatment selection: strong evidence with a known blind spot

In its recommendations, the Precision Medicine Working Group of the European Society for Medical Oncology (ESMO) stated that ctDNA assays which are validated and sufficiently sensitive are suitable for routine use in finding actionable mutations in advanced cancer, as long as their limitations are recognised.61 Tissue remains the preferred sample in many situations because plasma assays detect fusions and copy-number changes less reliably, but plasma testing is appropriate when a faster result matters or when tissue cannot be obtained.61 The key limitation is asymmetric. A positive plasma result for a validated driver can generally be acted upon, whereas a negative result may simply reflect low tumour shedding. Laboratories should therefore state explicitly on negative reports that tissue testing is recommended when clinically feasible. The same asymmetry explains why plasma-first strategies work best in tumours that shed abundantly and poorly in tumours with low shedding, such as gliomas and some renal cancers.14

Molecular residual disease: prognostic, but is it actionable?

Observational studies agree that finding ctDNA after curative surgery singles out patients who are likely to relapse. GALAXY followed 1039 patients with resectable colorectal cancer: those with detectable ctDNA 4 weeks after the operation had roughly ten times the recurrence risk of those without, and ctDNA status outweighed every other prognostic factor in stage II–III disease.78 A prognostic marker, however, is not necessarily a useful guide to treatment. DYNAMIC, a randomised trial in stage II colon cancer, tested this directly. Of its 455 patients, 15% of those managed according to their ctDNA result received adjuvant chemotherapy, compared with 28% of those managed conventionally, and 2-year recurrence-free survival in the ctDNA arm (93.5%) was non-inferior to that in the standard arm (92.4%).79 This result supports withholding chemotherapy from ctDNA-negative patients with stage II disease, but it does not show that intensifying treatment for ctDNA-positive patients improves survival, and it cannot be assumed to apply to other stages or tumour types.

Several interpretive issues follow for the laboratory. A single negative postoperative test does not exclude residual disease, because some patients shed too little DNA to be detected; serial sampling improves sensitivity but raises cost. Tumour-informed assays are more sensitive but need tissue and time to design, which can delay results beyond the window for starting adjuvant therapy. Results also depend on the timing of the blood draw, because surgery itself temporarily increases the amount of normal cfDNA. Reports should therefore state the assay type, the interval since surgery, and the limit of detection, and a single negative result should be interpreted as lowering, not removing, the risk of recurrence.37,62

Multi-cancer early detection: specificity is not enough

Because they are intended for people without symptoms, MCED tests are tuned for very high specificity so that few healthy people receive a false alarm. When a targeted methylation assay was checked in the independent validation cohort of the CCGA (Circulating Cell-free Genome Atlas) study, only 0.5% of people without cancer tested positive, yet the test picked up just over half of all cancers (51.5%) and only about one in six stage I cancers (16.8%).80 PATHFINDER, a prospective study, offered the test to 6621 people aged 50 years or older. Ninety-two (1.4%) had a positive result, and cancer was confirmed in 35, so the positive predictive value was 38%.81 Most positive results were therefore false and led to diagnostic work-up, while many cancers diagnosed during follow-up were not detected by the test. Low sensitivity for early-stage disease is the central problem, because stage I and II cancers are those for which earlier detection is most likely to save lives. Mortality benefit has not been shown, and the use of stage shift as a surrogate end point has been questioned.56,57 Until randomised mortality data are available, MCED testing should be offered only within studies or with careful informed consent, and it should not replace established screening for breast, cervical, colorectal, or lung cancer.

Clonal haematopoiesis and other sources of false results

Clonal haematopoiesis is the most important biological cause of false-positive ctDNA results. Razavi and colleagues sequenced cfDNA at very high depth in 47 people without cancer and 124 with metastatic disease; the majority of the plasma mutations they found bore the hallmarks of clonal haematopoiesis, accounting for 81.6% in the control group and 53.2% in the cancer group.82 Without paired white-cell sequencing, a plasma variant in a gene commonly affected by clonal haematopoiesis cannot be confidently attributed to the tumour. This has two practical consequences for laboratories: the buffy coat should be retained at processing so that paired analysis is possible, and reports should flag such variants when paired analysis has not been performed.61,82 Other sources of error, including white-cell lysis during delayed processing, extraction variability, and sequencing artefacts at low allele fractions, are largely controllable through the measures described in Sections 3.5 and 4.5.30,36

Implications for clinical biochemistry laboratories and LMIC settings

The evidence above suggests a staged approach, particularly in India and other LMICs. The first stage is pre-analytical: written protocols for tube type, maximum time to centrifugation, two-step centrifugation, buffy-coat retention, and storage, supported by audit of compliance. The second is a narrow, validated test menu matched to the strongest evidence, beginning with plasma genotyping in advanced NSCLC. The third is quality assurance, including reference materials near the limit of detection and participation in external quality assessment. MRD and MCED testing should follow only when local data, reimbursement, and clinical pathways are in place. This sequence directs investment to where the evidence is strongest and where laboratory practice has the greatest influence on result quality. It also recognises that the cost of an incorrect result, whether an unnecessary treatment or a missed alteration, falls most heavily on patients and health systems with the fewest resources.75

Gaps in the evidence

Four gaps stand out. Randomised evidence that MRD-guided treatment improves survival is lacking outside stage II colon cancer. MCED tests have no mortality data, and their performance in Asian and other non-European populations is poorly characterised. Few studies compare commercial assays head to head on the same samples. Finally, cost-effectiveness studies from LMICs are scarce, so most economic arguments rely on data from high-income settings.75,83

Limitations

Our review has limitations that readers should keep in mind. Its design is narrative: the search was structured but not registered in advance, one author selected studies with a second consulted on uncertain cases, and study quality was not formally scored, so selection bias cannot be excluded. Articles not written in English were left out, which may under-represent experience from other regions. The field changes quickly, and studies and regulatory decisions after December 2025 are not covered. No meta-analysis was attempted because indications, analytes, and platforms were too heterogeneous for pooling. The restriction to ctDNA in solid tumours means that promising work on other analytes is covered only briefly. Finally, the discussion of implementation in LMICs draws mainly on Indian experience and may not apply to all resource-limited settings.

Future Directions

Multi-omics integration

Single-analyte tests are being complemented by multi-omic approaches that combine cfDNA methylation, fragment patterns, cfRNA, and vesicle-borne proteins and nucleic acids.84 Combining these layers improves sensitivity for early detection and the accuracy of tissue-of-origin prediction.39,84

Computational analysis and artificial intelligence

Multi-omic studies of blood samples produce more data than can be interpreted without artificial intelligence (AI) and machine learning. Classifiers of this kind have been trained on cfDNA fragment patterns, vesicle protein profiles, and methylation data, both to separate people with and without cancer and to predict where a tumour arose.85 Before clinical use they will need testing in independent cohorts and reporting that meets current standards for AI in medicine.85

Portable and decentralised testing

Microfluidic sample preparation, isothermal amplification, and CRISPR- or biosensor-based readout are being combined in portable cartridge systems for decentralised testing.47 If they can be produced at low cost, such systems could bring treatment selection and monitoring to settings without a central molecular laboratory.

Predictive biomarkers

Candidate predictive markers include ctDNA kinetics during immune-checkpoint therapy and fragment features associated with treatment response.38,62 These markers need prospective validation in interventional trials, rather than retrospective cohorts, before they can guide treatment.

Translational research models and trial design

Trials are exploring adaptive designs with ctDNA end points, including clearance of ctDNA as an early sign of response.83 NHS-Galleri illustrates how a pragmatic, population-wide trial can evaluate a screening test,55 and further trials are examining whether treatment in colorectal and breast cancer can be intensified or reduced according to ctDNA findings.83 International networks that share biobanks and data could produce evidence faster and avoid repeating the same study in different countries.83

Conclusion

ctDNA testing is now a valuable complement to tissue diagnosis in solid tumours. It needs only a blood sample, can be repeated as often as required, and reflects the whole tumour burden rather than one biopsy site, all of which suit precision oncology. The evidence, however, justifies routine use in only a few settings: genotyping of advanced cancer from plasma and, increasingly, assessment of residual disease in colorectal cancer. MCED should remain within research, or be offered only with careful consent, until it is shown to reduce deaths. What now limits ctDNA testing is less the analytical technology than sample handling, interpretation, and cost. Clinical biochemistry laboratories can tackle these directly by standardising pre-analytical steps, keeping the buffy coat for white-cell comparison, validating a small test menu against the best evidence, and joining external quality assessment schemes. In India and other LMICs, these steps will do more for reliable, affordable testing than any new platform.

Statements and Declarations

Funding
No organisation provided financial support for this work or for the preparation of the manuscript.
Clinical trial number
Not applicable. As a narrative review of published literature, this article reports no clinical trial, so trial registration was not needed.
Competing interests
None of the authors has any financial or non-financial interest relevant to this article.
Ethics approval
Not applicable. The review is based solely on published peer-reviewed literature; the authors conducted no new research involving human participants or animals.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Data availability
No new datasets were produced or analysed for this review; all material discussed is available in the cited publications.
Authors' contributions
Conceptualisation: Palani Selvam Mohanraj, Anupriya Velu. Literature search and data extraction: Anupriya Velu. Critical analysis and interpretation: Palani Selvam Mohanraj, Vinoth Rajendran, Suresh K Srinivasan. Writing — original draft preparation: Anupriya Velu. Writing — review and editing: Palani Selvam Mohanraj, Vinoth Rajendran, Suresh K Srinivasan. Supervision: Palani Selvam Mohanraj. The final manuscript was approved by all authors.
Use of artificial intelligence-assisted technologies
The authors used Claude (Anthropic), an AI writing tool, while revising this manuscript to reorganise the text and improve its language. All content was then checked and edited by the authors, who confirmed the cited sources and accept full responsibility for the final version.

Abbreviations

  • AI: artificial intelligence
  • ALK: anaplastic lymphoma kinase
  • CDSCO: Central Drugs Standard Control Organisation
  • cfDNA: cell-free DNA
  • cfRNA: cell-free RNA
  • CHIP: clonal haematopoiesis of indeterminate potential
  • CRISPR: clustered regularly interspaced short palindromic repeats
  • CSF: cerebrospinal fluid
  • CTC: circulating tumour cell
  • ctDNA: circulating tumour DNA
  • ddPCR: droplet digital polymerase chain reaction
  • EGFR: epidermal growth factor receptor
  • EMA: European Medicines Agency
  • ESMO: European Society for Medical Oncology
  • EV: extracellular vesicle
  • FDA: Food and Drug Administration
  • ICMR: Indian Council of Medical Research
  • KRAS: Kirsten rat sarcoma viral oncogene homologue
  • LMIC: low- and middle-income country
  • MCED: multi-cancer early detection
  • miRNA: microRNA
  • MRD: molecular residual disease
  • NGS: next-generation sequencing
  • NHS: National Health Service
  • NSCLC: non-small-cell lung cancer
  • NTRK: neurotrophic tyrosine receptor kinase
  • NULISA: nucleic acid-linked immuno-sandwich assay
  • PCR: polymerase chain reaction
  • RCT: randomised controlled trial
  • SHERLOCK: specific high-sensitivity enzymatic reporter unlocking
  • TEP: tumour-educated platelet

References

  1. Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease study. JAMA Oncol. 2019;5(12):1749-1768. doi:10.1001/jamaoncol.2019.2996
  2. Kocarnik JM, Compton K, Dean FE, et al; Global Burden of Disease 2019 Cancer Collaboration. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease study 2019. JAMA Oncol. 2022;8(3):420-444. doi:10.1001/jamaoncol.2021.6987
  3. Chintapally N, Nuwayhid M, Arroju V, et al. State of cancer care in India and opportunities for innovation. Future Oncol. 2023;19(39):2593-2606. doi:10.2217/fon-2023-0047
  4. Sathishkumar K, Chaturvedi M, Das P, Stephen S, Mathur P. Cancer incidence estimates for 2022 & projection for 2025: result from National Cancer Registry Programme, India. Indian J Med Res. 2022;156(4&5):598-607. doi:10.4103/ijmr.ijmr_1821_22
  5. Ma L, Guo H, Zhao Y, et al. Liquid biopsy in cancer: current status, challenges and future prospects. Signal Transduct Target Ther. 2024;9(1):336. doi:10.1038/s41392-024-02021-w
  6. Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79. doi:10.1186/s12943-022-01543-7
  7. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238. doi:10.1038/nrc.2017.7
  8. Di Zazzo E, Intrieri M, Davinelli S. Liquid biopsy and cancer: an ongoing story. J Clin Med. 2023;12(7):2690. doi:10.3390/jcm12072690
  9. Calandri M, Siravegna G, Yevich SM, et al. Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. Eur Radiol. 2020;30(8):4496-4503. doi:10.1007/s00330-020-06700-4
  10. Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. J Clin Invest. 2022;132(12):e154941. doi:10.1172/JCI154941
  11. Hoshino A, Kim HS, Bojmar L, et al. Extracellular vesicle and particle biomarkers define multiple human cancers. Cell. 2020;182(4):1044-1061.e18. doi:10.1016/j.cell.2020.07.009
  12. Mader S, Pantel K. Liquid biopsy: current status and future perspectives. Oncol Res Treat. 2017;40(7-8):404-408. doi:10.1159/000478018
  13. Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. doi:10.1186/s13045-022-01351-y
  14. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921. doi:10.1126/scitranslmed.aat4921
  15. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990. doi:10.1038/nm.1789
  16. Loy C, Ahmann L, De Vlaminck I, Gu W. Liquid biopsy based on cell-free DNA and RNA. Annu Rev Biomed Eng. 2024;26(1):169-195. doi:10.1146/annurev-bioeng-110222-111259
  17. Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells. 2019;8(7):727. doi:10.3390/cells8070727
  18. Yu D, Li Y, Wang M, et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022;21(1):56. doi:10.1186/s12943-022-01509-9
  19. Lai JJ, Chau ZL, Chen SY, et al. Exosome processing and characterization approaches for research and technology development. Adv Sci (Weinh). 2022;9(15):e2103222. doi:10.1002/advs.202103222
  20. Ailuno G, Baldassari S, Lai F, Florio T, Caviglioli G. Exosomes and extracellular vesicles as emerging theranostic platforms in cancer research. Cells. 2020;9(12):2569. doi:10.3390/cells9122569
  21. In 't Veld SGJG, Wurdinger T. Tumor-educated platelets. Blood. 2019;133(22):2359-2364. doi:10.1182/blood-2018-12-852830
  22. Ding S, Dong X, Song X. Tumor educated platelet: the novel BioSource for cancer detection. Cancer Cell Int. 2023;23(1):91. doi:10.1186/s12935-023-02927-5
  23. Zhang Q, Song X, Song X. Contents in tumor-educated platelets as the novel biosource for cancer diagnostics. Front Oncol. 2023;13:1165600. doi:10.3389/fonc.2023.1165600
  24. Ding Z, Wang N, Ji N, Chen ZS. Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022;21(1):53. doi:10.1186/s12943-022-01526-8
  25. Goodsaid FM. The labyrinth of product development and regulatory approvals in liquid biopsy diagnostics. Clin Transl Sci. 2019;12(5):431-439. doi:10.1111/cts.12657
  26. Kalligosfyri PM, Lamprou E, Kalogianni DP. Emerging sensing technologies for liquid biopsy applications: steps closer to personalized medicine. Sensors (Basel). 2024;24(24):7902. doi:10.3390/s24247902
  27. van der Pol Y, Tantyo NA, Evander N, et al. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing. EMBO Mol Med. 2023;15(12):e17282. doi:10.15252/emmm.202217282
  28. Salfer B, Havo D, Kuppinger S, Wong DTW, Li F, Zhang L. Evaluating pre-analytical variables for saliva cell-free DNA liquid biopsy. Diagnostics (Basel). 2023;13(10):1665. doi:10.3390/diagnostics13101665
  29. Song P, Wu LR, Yan YH, et al. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng. 2022;6(3):232-245. doi:10.1038/s41551-021-00837-3
  30. Grölz D, Hauch S, Schlumpberger M, et al. Liquid biopsy preservation solutions for standardized pre-analytical workflows—venous whole blood and plasma. Curr Pathobiol Rep. 2018;6(4):275-286. doi:10.1007/s40139-018-0180-z
  31. Sorber L, Zwaenepoel K, Jacobs J, et al. Circulating cell-free DNA and RNA analysis as liquid biopsy: optimal centrifugation protocol. Cancers (Basel). 2019;11(4):458. doi:10.3390/cancers11040458
  32. Hindson BJ, Ness KD, Masquelier DA, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem. 2011;83(22):8604-8610. doi:10.1021/ac202028g
  33. Galimberti S, Balducci S, Guerrini F, Del Re M, Cacciola R. Digital droplet PCR in hematologic malignancies: a new useful molecular tool. Diagnostics (Basel). 2022;12(6):1305. doi:10.3390/diagnostics12061305
  34. Chen M, Zhao H. Next-generation sequencing in liquid biopsy: cancer screening and early detection. Hum Genomics. 2019;13(1):34. doi:10.1186/s40246-019-0220-8
  35. Lin C, Liu X, Zheng B, Ke R, Tzeng CM. Liquid biopsy, ctDNA diagnosis through NGS. Life (Basel). 2021;11(9):890. doi:10.3390/life11090890
  36. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547-555. doi:10.1038/nbt.3520
  37. Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers (Basel). 2021;13(21):5364. doi:10.3390/cancers13215364
  38. van 't Erve I, Alipanahi B, Lumbard K, et al. Cancer treatment monitoring using cell-free DNA fragmentomes. Nat Commun. 2024;15(1):8801. doi:10.1038/s41467-024-53017-7
  39. Shen SY, Singhania R, Fehringer G, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563(7732):579-583. doi:10.1038/s41586-018-0703-0
  40. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. Nat Protoc. 2019;14(10):2986-3012. doi:10.1038/s41596-019-0210-2
  41. Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438-442. doi:10.1126/science.aam9321
  42. Selvakumar SC, Preethi KA, Ross K, et al. CRISPR/Cas9 and next generation sequencing in the personalized treatment of cancer. Mol Cancer. 2022;21(1):83. doi:10.1186/s12943-022-01565-1
  43. Nanou A, Coumans FAW, van Dalum G, et al. Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients. Oncotarget. 2018;9(27):19283-19293. doi:10.18632/oncotarget.25019
  44. Lischnig A, Bergqvist M, Ochiya T, Lässer C. Quantitative proteomics identifies proteins enriched in large and small extracellular vesicles. Mol Cell Proteomics. 2022;21(9):100273. doi:10.1016/j.mcpro.2022.100273
  45. Vlachová M, Pečinka L, Gregorová J, et al. Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients. Sci Rep. 2024;14(1):18777. doi:10.1038/s41598-024-69408-1
  46. Iwano T, Yoshimura K, Watanabe G, et al. High-performance collective biomarker from liquid biopsy for diagnosis of pancreatic cancer based on mass spectrometry and machine learning. J Cancer. 2021;12(24):7477-7487. doi:10.7150/jca.63244
  47. Kalogianni DP. Nanotechnology in emerging liquid biopsy applications. Nano Converg. 2021;8(1):13. doi:10.1186/s40580-021-00263-w
  48. Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14(1):7238. doi:10.1038/s41467-023-42834-x
  49. Ossandon MR, Agrawal L, Bernhard EJ, et al. Circulating tumor DNA assays in clinical cancer research. J Natl Cancer Inst. 2018;110(9):929-934. doi:10.1093/jnci/djy105
  50. Sumbal S, Javed A, Afroze B, et al. Circulating tumor DNA in blood: future genomic biomarkers for cancer detection. Exp Hematol. 2018;65:17-28. doi:10.1016/j.exphem.2018.06.003
  51. Chen D, Mo H, Zhang Y, et al. Development and implementation of an internal quality control and external quality assessment information system for a regional medical laboratory center: pilot design and implementation study. JMIR Form Res. 2025;9:e77043. doi:10.2196/77043
  52. Pinsky PF. Principles of cancer screening. Surg Clin North Am. 2015;95(5):953-966. doi:10.1016/j.suc.2015.05.009
  53. Milner DA, Lennerz JK. Technology and future of multi-cancer early detection. Life (Basel). 2024;14(7):833. doi:10.3390/life14070833
  54. Loud JT, Murphy J. Cancer screening and early detection in the 21st century. Semin Oncol Nurs. 2017;33(2):121-128. doi:10.1016/j.soncn.2017.02.002
  55. Neal RD, Johnson P, Clarke CA, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers (Basel). 2022;14(19):4818. doi:10.3390/cancers14194818
  56. Callister MEJ, Crosbie EJ, Crosbie PAJ, Robbins HA. Evaluating multi-cancer early detection tests: an argument for the outcome of recurrence-updated stage. Br J Cancer. 2023;129(8):1209-1211. doi:10.1038/s41416-023-02434-4
  57. Rubinstein WS, Patriotis C, Dickherber A, et al. Cancer screening with multicancer detection tests: a translational science review. CA Cancer J Clin. 2024;74(4):368-382. doi:10.3322/caac.21833
  58. Meng Y, Sun J, Zheng Y, Zhang G, Yu T, Piao H. Platelets: the emerging clinical diagnostics and therapy selection of cancer liquid biopsies. Onco Targets Ther. 2021;14:3417-3428. doi:10.2147/OTT.S311907
  59. Li W, Liu JB, Hou LK, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1):25. doi:10.1186/s12943-022-01505-z
  60. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731-747. doi:10.1038/s41571-018-0113-0
  61. Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750-768. doi:10.1016/j.annonc.2022.05.520
  62. Sanz-Garcia E, Zhao E, Bratman SV, Siu LL. Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: current research, opportunities, and challenges. Sci Adv. 2022;8(4):eabi8618. doi:10.1126/sciadv.abi8618
  63. Chidharla A, Rapoport E, Agarwal K, et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int J Mol Sci. 2023;24(12):10230. doi:10.3390/ijms241210230
  64. Fernández-Lázaro D, García Hernández JL, Caballero García A, Caballero del Castillo A, Villaverde Hueso M, Cruz-Hernández JJ. Clinical perspective and translational oncology of liquid biopsy. Diagnostics (Basel). 2020;10(7):443. doi:10.3390/diagnostics10070443
  65. Hofman P. Detecting resistance to therapeutic ALK inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice. Cells. 2021;10(1):168. doi:10.3390/cells10010168
  66. Roweth HG, Battinelli EM. Lessons to learn from tumor-educated platelets. Blood. 2021;137(23):3174-3180. doi:10.1182/blood.2019003976
  67. Janssen FW, Lak NSM, Janda CY, et al. A comprehensive overview of liquid biopsy applications in pediatric solid tumors. NPJ Precis Oncol. 2024;8(1):172. doi:10.1038/s41698-024-00657-z
  68. Sundby RT, Pan A, Shern JF. Liquid biopsies in pediatric oncology: opportunities and obstacles. Curr Opin Pediatr. 2022;34(1):39-47. doi:10.1097/MOP.0000000000001088
  69. Tripathy A, John V, Wadden J, Kong S, Sharba S, Koschmann C. Liquid biopsy in pediatric brain tumors. Front Genet. 2023;13:1114762. doi:10.3389/fgene.2022.1114762
  70. Sathyanarayana SH, Spracklin SB, Deharvengt SJ, et al. Standardized workflow and analytical validation of cell-free DNA extraction for liquid biopsy using a magnetic bead-based cartridge system. Cells. 2025;14(14):1062. doi:10.3390/cells14141062
  71. Simarro J, Murria R, Pérez-Simó G, et al. Development, implementation and assessment of molecular diagnostics by next generation sequencing in personalized treatment of cancer: experience of a public reference healthcare hospital. Cancers (Basel). 2019;11(8):1196. doi:10.3390/cancers11081196
  72. Gogtay NJ, Ravi R, Thatte UM. Regulatory requirements for clinical trials in India: what academicians need to know. Indian J Anaesth. 2017;61(3):192-199. doi:10.4103/ija.IJA_143_17
  73. Roche MI, Berg JS. Incidental findings with genomic testing: implications for genetic counseling practice. Curr Genet Med Rep. 2015;3(4):166-176. doi:10.1007/s40142-015-0075-9
  74. Srivastava S, Koay EJ, Borowsky AD, et al. Cancer overdiagnosis: a biological challenge and clinical dilemma. Nat Rev Cancer. 2019;19(6):349-358. doi:10.1038/s41568-019-0142-8
  75. Qureshi Z, Altaf F, Khanzada M, et al. Liquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions. Ann Med Surg (Lond). 2025;87(6):3244-3253. doi:10.1097/MS9.0000000000002776
  76. Wallington-Beddoe CT, Mynott RL. Prognostic and predictive biomarker developments in multiple myeloma. J Hematol Oncol. 2021;14(1):151. doi:10.1186/s13045-021-01162-7
  77. Fountzilas E, Tsimberidou AM, Vo HH, Kurzrock R. Clinical trial design in the era of precision medicine. Genome Med. 2022;14(1):101. doi:10.1186/s13073-022-01102-1
  78. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127-134. doi:10.1038/s41591-022-02115-4
  79. Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261-2272. doi:10.1056/NEJMoa2200075
  80. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi:10.1016/j.annonc.2021.05.806
  81. Schrag D, Beer TM, McDonnell CH 3rd, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402(10409):1251-1260. doi:10.1016/S0140-6736(23)01700-2
  82. Razavi P, Li BT, Brown DN, et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med. 2019;25(12):1928-1937. doi:10.1038/s41591-019-0652-7
  83. Parisi C, Tagliamento M, Belcaid L, et al. Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications. J Liq Biopsy. 2023;1:100007. doi:10.1016/j.jlb.2023.100007
  84. Bao Y, Zhang D, Guo H, Ma W. Beyond blood: advancing the frontiers of liquid biopsy in oncology and personalized medicine. Cancer Sci. 2024;115(4):1060-1072. doi:10.1111/cas.16097
  85. Luo X, Xie S, Hong F, et al. From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening. Biomark Res. 2026;14(1):3. doi:10.1186/s40364-025-00874-z

Article information

Authors

  • Anupriya VeluDepartment of Biochemistry, Faculty of Medicine, Shri Gorakshnath Medical College, Hospital and Research Center, Mahayogi Gorakhnath University, Gorakhpur, India
  • Suresh K SrinivasanDirector of Pain Medicine, Trinity Health System, Steubenville, OH 43952, United States
  • Palani Selvam MohanrajDepartment of Biochemistry, All India Institute of Medical Sciences, Gorakhpur, IndiaCorresponding author · [email protected]
  • Vinoth RajendranDepartment of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, India

How to cite

Velu, A., Srinivasan, S. K., et al., 2026. Circulating Tumour DNA-Based Liquid Biopsy in Oncology: Analytical Foundations, Clinical Evidence, and Laboratory Implementation. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0640

Record

Journal
Medical Research Archives
Section
Review Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
199

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.